FPRX Five Prime Therapeutics Inc.

5.36
+0.02  (+0%)
Previous Close 5.34
Open 5.35
Price To Book 0.95
Market Cap 197,148,224
Shares 36,781,385
Volume 76,787
Short Ratio
Av. Daily Volume 298,657

NewsSee all news

  1. Five Prime Therapeutics to Present at Upcoming Healthcare Conference

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 futility analysis due 1H 2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 1b ongoing.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Solid tumors
Phase 2 complete. Phase 3 development will not be pursued.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
FP-1039
Mesothelioma cancer
Phase 1b initial data due at ESMO September 30, 2019.
FPA150
Solid tumors
Phase 2 trial initiated January 2018.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Pancreatic cancer
Phase 1 dosing announced November 14, 2018. Data due at SITC 2019.
FPT155
Solid tumors

Latest News

  1. Five Prime Therapeutics to Present at Upcoming Healthcare Conference

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief